8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

Form 8-K

_________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): December 12, 2019

BEIGENE, LTD.

(Exact Name of Registrant as Specified in Charter)

Cayman Islands	001-37686	98-1209416
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands

(Address of Principal Executive Offices) (Zip Code)

+1 (345) 949-4123

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share	BGNE	The NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*	06160	The Stock Exchange of Hong Kong Limited

*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure.

BeiGene, Ltd. (the “Company”) hosted an investor conference call and webcast of results of its Phase 3 ASPEN trial on December 16, 2019. A copy of the Company’s presentation used during the conference call and webcast is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in Item 7.01 of this Current Report on Form 8-K, including the presentation, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing or this Current Report.

Item 8.01. Other Events.

On December 12, 2019, the Company issued a press release announcing preliminary data from an ongoing Phase 1b trial of investigational anti-PD-1 antibody tislelizumab in combination with investigational tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer, which demonstrated antitumor activity and was generally well tolerated. Results from the Phase 1b clinical trial were presented at the 2019 European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress on December 13, 2019 in Geneva, Switzerland. The full text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

On December 16, 2019, the Company issued a press release announcing results from the Phase 3 ASPEN trial comparing its BTK inhibitor BRUKINSA™ (zanubrutinib) to ibrutinib for the treatment of Waldenström’s macroglobulinemia (WM). While the trial did not achieve statistical significance on its primary endpoint of superiority in complete response (CR) and very good partial response (VGPR) rates for zanubrutinib compared to ibrutinib, zanubrutinib demonstrated a higher VGPR rate as well as improvements in safety and tolerability in this first randomized comparative trial to read out within the BTK inhibitor class. The full text of this press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Company Presentation dated December 16, 2019
99.2	Press Release issued on December 12, 2019
99.3	Press Release issued on December 16, 2019
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Exhibit Index

Exhibit No.	Description
99.1	Company Presentation dated December 16, 2019
99.2	Press Release issued on December 12, 2019
99.3	Press Release issued on December 16, 2019
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BEIGENE, LTD.
Date: December 16, 2019	By:	/s/ Scott A. Samuels
	Name:	Scott A. Samuels
	Title:	Senior Vice President, General Counsel

EX-99.1

Exhibit 99.1 ASPEN Results Conference Call December 16, 2019

Howard Liang, Ph.D. CFO and Chief Strategy Officer 2

Agenda Welcome – Howard Liang Introduction – John Oyler ASPEN Results – Jane Huang BRUKINSA Development – Eric Hedrick BRUKINSA Commercialization – Josh Neiman Concluding Remarks – John Oyler Q&A 3

• Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding clinical data for patients from the ASPEN trial and advantages compared to ibrutinib; plans for regulatory discussions and submission of data from the ASPEN trial; the launch and potential commercial opportunity of BRUKINSA in the United States; BeiGene’s plans and expectations for Disclosures further development and potential commercialization of XGEVA, KYPROLIS, BLINCYTO and Amgen’s oncology pipeline assets; the timing of approvals of BeiGene’s commercial products in China; BeiGene’s further advancement of, and anticipated clinical development, regulatory milestones and commercialization of its drug candidates; and continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BeiGene’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which BeiGene does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from BeiGene’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, including from the FDA, NMPA (formerly CFDA/CDA) and EMA, the possibility of having to conduct additional clinical trials and BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services. Further, even if regulatory approval is obtained,1 pharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in BeiGene’s filings with the Securities and Exchange Commission (SEC) and Hong Kong Stock Exchange. The reader should not place undue reliance on any forward-looking statements included in this presentation or in the accompanying oral presentation. These statements speak only as of the date made, and BeiGene is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. • Some of the clinical data in this presentation relating to BeiGene’s investigational drug candidates is from early phase, single-arm trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between BeiGene’s investigational drug candidates and other products. BeiGene is still conducting clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene’s investigational drug candidates may change. • This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above. 4

John V. Oyler Chairman, Co-founder & CEO 5

Jane Huang, M.D. Chief Medical Officer, Hematology 6

Executive Summary • ASPEN is the first randomized Phase 3 study comparing two BTK inhibitors in any indication & the largest prospective randomized Phase 3 study in Waldenström’s Macroglobulinemia (WM) • The difference in the primary endpoint of the study (VGPR+CR rate: 28.9% zanubrutinib vs 19.8% ibrutinib, 2-sided p=0.116) in relapsed/refractory patients did not meet statistical significance • PFS and OS data at 12 months were consistent with the higher rate of VGPR with zanubrutinib ─ Supports our underlying hypothesis that sustained target occupancy may produce meaningful improvement in efficacy ─ Further follow-up will be required to ultimately define the clinical benefit of zanubrutinib relative to ibrutinib in WM • Importantly, the safety analysis showed clinically meaningful differences in favor of zanubrutinib, including differences in atrial fibrillation, serious bleeding, serious infection, diarrhea, and events leading to treatment discontinuation 7

ASPEN: A Phase 3 Study of Zanubrutinib vs Ibrutinib in Waldenström’s Macroglobulinemia Study Design Primary endpoint: CR or VGPR, per modified IWWM6, by independent review Arm A Cohort 1: R/R or TN* WM with MYD88L265P mutation Secondary Endpoints: Zanubrutinib 1) MRR (>PR) 160 mg BID until PD 2) PFS N=102 3) Duration of response MYD88MUT WM (R/R=83, TN=19) 4) Safety R patients Analysis Populations: (N=201, 164 R/R) 1:1 - Efficacy: ITT, R/R and Overall Arm B - Safety: all patients receiving at least 1 dose Ibrutinib Stratification factors: Analysis Plan: • CXCR4 status (WHIM vs WT) 420mg QD until PD - Hierarchical analysis: relapsed/ refractory • No. of lines of prior therapy N=99 population followed by overall population (if (0 vs 1-3 vs >3) (R/R= 81, TN= 18) endpoint met in relapsed/ refractory *TN must be unsuitable for standard chemoimmunotherapy population) Cohort 2: WM with wild type MYD88 Enrollment Period: 1/2017-7/2018 Enrollment by region: Cohort 1 Arm C - Europe: 120 pts (59.7%) MYD88WT WM patients Zanubrutinib - Australia: 62 pts (30.8%) (N = 26) 160 mg BID until PD - US: 19 pts (9.5%) Data Cut-off: August 31, 2019 Median Follow-up: 19.4 months WM=Waldenström’s macroglobulinemia, BID=twice daily, CR=complete response, MUT=mutation, PD=progressive disease, QD=once daily, R=randomization, R/R=relapsed/refractory, TN=treatment naïve, VGPR=very good partial response, WT=wild type. This study is registered at ClinicalTrials.gov (NCT03053440) Source: EHA 2019, abstract PF487. a. One patient achieved IgM complete response (normalized IgM and negative immunofixation since Cycle 11, with bulky extramedullary disease improving). b. Including pts confirmed by next-generation sequencing of no other activating MYD88 mutations: 3 of 6 VGPR (including IgM CR); 3 of 8 PR. 8

Efficacy Summary Primary Endpoint Response Rate Relapsed or Refractory Overall Zanubrutinib Ibrutinib Zanubrutinib Ibrutinib (N = 83) (N = 81) (N = 102) (N = 99) CR 0 0 0 0 VGPR 24 (28.9) 16 (19.8) 29 (28.4) 19 (19.2) PR 41 (49.4) 49 (60.5) 50 (49.0) 58 (58.6) MR 13 (15.7) 11 (13.6) 17 (16.7) 15 (15.2) No response 4 (4.8) 4 (4.9) 5 (4.9) 5 (5.0) VGPR+CR rate, % 24 (28.9) 16 (19.8) 29 (28.4) 19 (19.2) (CI) (19.5, 39.9) (11.7, 30.1) (19.9, 38.2) (12.0, 28.3) Major response rate (PR+), % 65 (78.3) 65 (80.2) 79 (77.5) 77 (77.8) (CI) (67.9, 86.6) (69.9, 88.3) (68.1, 85.1) (68.3, 85.5) Objective response rate (MR+), % 78 (94.0) 76 (93.8) 96 (94.1) 92 (92.9) (CI) (86.5, 98.0) (86.2, 98.0) (87.6, 97.8) (86.0, 97.1) * Groups were generally well-balanced for number of prior therapies, IPSS score, baseline IgM, and baseline hematologic parameters. Overall CXCR4 mutation was 10.9%

Efficacy Summary Landmark Data PFS and OS* Relapsed or Refractory Overall Zanubrutinib Ibrutinib Zanubrutinib Ibrutinib (N = 83) (N = 81) (N = 102) (N = 99) 6-month PFS, % 96.3 91.1 95.0 91.6 (CI) (88.9 - 98.8) (82.3 - 95.7) (88.4 - 97.9) (83.9 - 95.7) 12-month PFS, % 92.4 85.9 89.7 87.2 (CI) (83.8 - 96.5) (75.9 - 91.9) (81.7 - 94.3) (78.6 - 92.5) 6-month OS, % 98.8 95.0 98.0 95.9 (CI) (91.6 - 99.8) (87.3 - 98.1) (92.2 - 99.5) (89.5 - 98.4) 12-month OS, % 98.8 92.5 97.0 93.9 (CI) (91.6 - 99.8) (84.1 - 96.6) (90.9 - 99.0) (86.8 - 97.2) * Groups were generally well-balanced for number of prior therapies, IPSS score, baseline IgM, and baseline hematologic parameters. Overall CXCR4 mutation was 10.9%. 12-month landmark data are mature.

Safety: Overall Summary Overall Zanubrutinib Ibrutinib (N =101) (N = 98) Any Adverse Event (AE) 98 (97%) 97 (99.0%) Grade 3 or Higher AE 59 (58.4%) 62 (63.3%) Serious Adverse Event (SAE) 40 (39.6%) 40 (40.8%) Fatal AE 1 (1%) 4 (4.1%) AE Leading to Treatment Discontinuation 4 (4%) 9 (9.2%) AE Leading to Leading to Dose Reduction 14 (13.9%) 23 (23.5%) 11

Adverse Events of Special Interest Overall Zanubrutinib Ibrutinib (N = 102) (N = 99) AEs of Interest, n, % Atrial fibrillation/flutter (all grades) 2 (2.0%) 15 (15.3%) Minor bleeding 49 (48.5%) 58 (59.2%) (bruising, contusion, petechiae) Major hemorrhage* 6 (5.9%) 9 (9.2%) Diarrhea (all grades) 21 (20.8%) 31 (31.6%) Infection 67 (66.3%) 66 (67.3%) Pneumonia/Lower respiratory 9 (8.9%) 19 (19.4%) tract infections Hypertension 11 (10.9%) 17 (17.3%) Hematologic Neutropenia 30 (29.7%) 13 (13.3%) Anemia 12 (11.9%) 10 (10.2%) Thrombocytopenia 10 (9.9%) 12 (12.2%) * Bleeding > grade 3, or CNS bleeding of any grade

ASPEN: Conclusions and Next Steps • In this Phase 3 study, the first randomized comparison of a highly-selective BTK inhibitor (zanubrutinib) with ibrutinib: ─ Statistical significance for the primary endpoint (VGPR or better) was not met ─ Clinically meaningful differences in safety favoring zanubrutinib were demonstrated ─ Early, landmark PFS and OS analyses are directionally consistent with the higher VGPR rate observed in the zanubrutinib arm • Next Steps: ─ Plan to present ASPEN data and submit manuscript for publication in 2020 ─ Discuss ASPEN data with both US FDA and EMA in 1H 2020 ─ Longer-term PFS and OS follow-up 13

BRUKINSA Development Update Eric Hedrick, M.D., Chief Advisor 14

Zanubrutinib Development Program • Broad clinical trials program intended to support the approval of zanubrutinib in MCL, WM, CLL, MZL, and FL • Best-in-class hypothesis (safety and efficacy) is being tested in head-to-head trials versus ibrutinib in WM and CLL ─ Complete and sustained BTK occupancy efficacy distinctions vs ibrutinib ─ Higher selectivity for BTK safety and tolerability advantages over ibrutinib • Recent US FDA approval in patients with relapsed/refractory (R/R) MCL • Anticipated China approval (1H 2020) in R/R MCL and R/R CLL • Key Phase 3/ registrational trials either completed (1L CLL) or expected to soon complete (1Q 2020 for R/R CLL and MZL) • Potential interim analysis read-out in 1L CLL in 2020 15

Brukinsa Broad Clinical Development Program Nine ongoing potentially registration-enabling studies Pivotal Phase 2 (n=86) in R/R MCL Filed, In NDA review zanu monotherapy, PE: ORR Phase 3 (n=500) in 1L MCL Phase 1/2 cohort (n=45) in MCL Initiated: Mar 2017, Enrollment complete: Sep 2017 R+zanu vs. R+chemo, PE: PFS zanu monotherapy, PE: Safety RP2D MCL Enrollment Complete NDA accepted by NMPA and approved by U.S. FDA in Initiated: Nov 2019 Initiated: Aug 2014 Nov. 2019 Enrolling Phase 3 (n=229) in WM (ASPEN) Pivotal Phase 2 (n=44) in R/R WM Phase 1/2 (n=73) in WM zanu vs. ibrutinib, PE: VGPR/CR, WM zanu monotherapy, PE: MRR zanu monotherapy, PE: Safety, RP2D Planned Initiated: Jan 2017, Enrollment complete: Jul 2018, Top- Initiated: Aug 2017, Enrollment complete: May 2018 Initiated: Aug 2014, Enrollment complete: July 2018 line data: Dec 2019 Filed or potentially registrational Pivotal Phase 2 (n=91) in R/R CLL/SLL Phase 3 (n=550) in 1L CLL/SLL (SEQUOIA) Phase 3 (n=400) in R/R CLL/SLL (ALPINE) zanu monotherapy, PE: ORR zanu vs. BR, PE: PFS, zanu vs. ibrutinib, PE: ORR Initiated: Mar 2017, Enrollment complete: Dec 2017 Initiated: Nov 2017, Enrollment complete^: Aug 2019 Initiated: Nov 2018 China CLL/ NDA accepted: NMPA SLL Phase 2 (n=60) in previously treated CLL/SLL Global Phase 1 cohort (n=69) in CLL/SLL (ibrutinib intolerant) zanu monotherapy, PE: Safety RP2D zanu monotherapy, PE: Frequency and severity of Initiated: Aug 2014 treatment-emergent AEs of interest Initiated: Nov 2019 Pivotal phase 2 (n=210) in R/R FL Phase 21 (n=65) in R/R MZL FL Obinutuzumab ± zanu, PE: ORR MZL zanu monotherapy, PE: ORR Phase 1b: zanu + ME-401, in B-cell malignancies Initiated: Nov 2017 Initiated: Feb 2019 Phase 2: zanu / venetoclax / Phase 1b/2: zanu + tislelizumab, Phase 1b: zanu + obinutuzumab, Phase 2: Monotherapy, R/R obinutuzumab in 1L CLL Non-GCB DLBCL B-cell malignancies R/R CLL (MSKCC study) CLL DLBCL Phase 1 in hematologic malignancies Phase 2: zanu / venetoclax / Phase 1b: zanu + Revlimid, Phase 1b: zanu + R-chemo, Bcl-2 inhibitor BGB-11417 Combination obinutuzumab in 1L CLL R/R DLBCL 1L and 2L DLBCL monotherapy and comb. with zanu (GCLLSG study) Planned: 1H 2020 ^Time of the announcement of the enrollment completion; 1L: First Line; CLL/SLL: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; CR: Complete Response; DLBCL: Diffuse Large B-Cell Lymphoma; FL: Follicular Lymphoma; GCB: Germinal Center B-cell-like; MCL: Mantle Cell Lymphoma; MRR: Major Response Rate; MZL: Marginal Zone Lymphoma; NHL: Non-Hodgkin’s Lymphoma; ORR: Overall Response Rate; PCNSL: Primary Central Nervous System Lymphoma; PE: Primary endpoint; PFS: Progression-Free Survival; RP2D: Recommended Phase 2 Dose; R/R: Relapsed / Refractory; RT: Richter’s Transformation; VGPR: Very Good Partial Response; WM: Waldenström’s Macroglobulinemia. 1. global trial and potentially registration-enabling in certain countries. 16

Ongoing Global Phase 3 Studies in CLL/SLL SEQUOIA and ALPINE Zanubrutinib vs. BR in 1L CLL/SLL Zanubrutinib vs. Ibrutinib in R/R CLL/SLL Cohort 1: Non–17p del TN CLL Arm A Must be not suitable for FCR Zanubrutinib Relapsed/Refractory CLL/SLL 160 mg BID until PD Arm A Previously (received ≥ 1 prior treatments) untreated R Zanubrutinib 160mg BID CLL patients 1:1 (N=420) (n = 200) Arm B R/R CLL/SLL ≥ 1 prior Bendamustine R Primary endpoint: PFS treatment + Rituximab (BR) 1:1 × 6 cycles (N=400) Arm B Ibrutinib 420mg QD Cohort 2: 17p del TN CLL (n = 200) Previously untreated Arm C Primary Endpoint: ORR (non-inferiority and superiority) 17p del CLL patients Zanubrutinib (N=110) 160 mg BID until PD Full trial enrollment completed in June 2019 Complete enrollment expected by early 2020 1L=first-line treatment, BID=twice daily, CLL=chronic lymphocytic leukemia, del=deleted, FCR=fludarabine, cyclophosphamide, and rituximab, ORR=overall response rate, PD=progressive disease, PFS=progression-free survival, QD=once daily, R=randomized, SLL=small lymphocytic lymphoma, TN=treatment naïve. These studies are registered at ClinicalTrials.gov (NCT03734016) and (NCT03336333). 17

Zanubrutinib Near-Term Events • Broad clinical trial program continues in multiple indications • We plan to discuss ASPEN data with U.S. FDA and EMA • SEQUOIA Phase 3 study in 1L CLL (zanubrutinib vs BR): enrollment completed ─ Potential interim PFS analysis and top-line read out in 2020 • ALPINE Phase 3 study in R/R CLL (zanubrutinib vs ibrutinib): expected enrollment completion by year end 2019 • MAGNOLIA Phase 2 in R/R MZL: enrollment complete expected in early 2020 • Approval of zanubrutinib in China for R/R MCL and R/R CLL expected in 1H 2020 18

BRUKINSA Commercial Update Josh Neiman, Head, U.S. Commercial 19

U.S. BRUKINSA Launch Progress BRUKINSA made commercially available within four days of November approval Josh Neiman Head, U.S. Commercial Flatiron Onyx Pharmaceuticals Genentech • patient support program launched within BRUKINSA™ (zanubrutinib) is minutes of approval approved in the U.S. for R/R MCL1 • Commercial team in field and focused on driving awareness of BeiGene and BRUKINSA BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% • Initial feedback from clinicians: median occupancy in peripheral blood cells ─ Impressed by response rates from 206 and 003 studies and the only BTK inhibitor with the ─ Appreciate QD / BID dosing flexibility and ability to flexibility to be taken once or twice daily combine with PPIs and H2-RAs ─ Encouraged by 100% median BTK occupancy ─ See BRUKINSA as a differentiated BTKi 1. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. PPIs = proton pump inhibitors; H2-RAs = H2 receptor antagonists. 20

John V. Oyler Chairman, Co-Founder & CEO 21

Concluding Remarks • Zanubrutinib’s broad program on track ─ Despite not reaching primary endpoint of superiority, ASPEN provides evidence suggesting differentiation in both efficacy and safety / tolerability for zanubrutinib in the first randomized comparative trial within the BTK inhibitor class. ─ Running broad clinical program including 9 pivotal trials continues with potential 1L CLL readout as early as 2020. ─ Given the efficacy and safety/tolerability differences seen in ASPEN are consistent with our mechanistic hypothesis, we look forward to understanding if these will read through to other indications • Company-wide continued execution on broader commercial and pipeline programs ─ A total of up to 9 Phase 3 or pivotal Phase 2 trial readouts expected in 2020 ─ China Tislelizumab approval expected for cHL in 2019 and for UC in 2020; we are launch ready ─ China Zanubrutinib approval expected 1H 2020 for CLL and MCL ─ Clinical/commercial pipeline of 14 assets entering 2020 (does not including Amgen portfolio of 23 assets) • On track to close Amgen transaction in early 2020 ─ Regulatory reviews completed ─ Shareholders’ meeting scheduled for December 27 • Solid financial position 22

Q&A

Thank You

Supporting Information

ASH 2019 - SEQUOIA 1L CLL/SLL BRUKINSA VS Bendamustine Rituximab del(17p) Cohort 26

SEQUOIA Study Design NCT03336333 Arm A: zanubrutinib Cohort 1 open-label without del(17p) Key Eligibility R 1:1 n ~ 450 Arm B: bendamustine + rituximab • Treatment-naïve CLL/SLL • Met iwCLL criteria for zanubrutinib Requirement for Arm C Cohort 2 Arm C: treatment 160 mg bid until PD, Central assessment of • ≥ 65 y of age OR with del(17p) del(17p) by FISH with unsuitable for n ~ 100 intolerable toxicity, or > 7% aberrant nuclei treatment with FCR end of study presenta • Anticoagulation and Opened After CYP3A inhibitors Accrual of allowed Cohort 3 Cohort 2 with del(17p) Arm D: zanubrutinib + venetoclax Recruiting n ~ 50 Endpoints for Arm C: ORR (IRC and investigator assessments), PFS, DOR, safety Response assessment: per modified iwCLL criteria for CLL1,2 and Lugano criteria for SLL3 (IRC and investigator assessments) bid, twice daily; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DOR, duration of response; FCR, fludarabine, cyclophosphamide, and rituximab; FISH, fluorescence in situ hybridization; IRC, independent review committee; iwCLL, international workshop on CLL; ORR, overall response rate; PD, progressive disease; PFS: progression-free survival; R, randomized. aTP53 mutational status was not centrally assessed prior to enrollment. 1. Hallek M, et al. Blood. 2008;111:5446-5456. 2. Cheson BD, et al. J Clin Oncol. 2012;30:2820-2822. 3. Cheson BD, et al. J Clin Oncol. 2014;32:3059-3067 27

Best Overall Response Investigator assessment Best Response, n (%) n = 109 Safety ORR (CR, PR, or PR-L), n (%) [95% CI]a 101 (92.7) [86.0-96.8] • 36.7% of patients (40/109) experienced CR 2 (1.9) at least one grade ≥3 adverse event (AE) PR 86 (78.9) and three patients discontinued PR-L 13 (11.9) treatment due to AEs; • The most common grade ≥3 AEs, SD 6 (5.6) occurring in more than two patients, PD 1 (0.9) were neutropenia (10.1%), pneumonia First assessment not reachedb 1 (0.9) (3.7%) and hypertension (2.8%); Media follow-up months (range) 10.0 (5.0-18.1) • 23.9% of patients (26/109) experienced at least one serious AE; and Months to response, PR-L or higher, median 2.79 (1.9-11.0) • One patient experienced a fatal AE, (range) pneumonia leading to sepsis and death, Months to response, PR or higher, median 2.81 (1.9-11.1) which was considered related to (range) treatment drug by the study investigator. Duration of response ≥ 6 mo, % [95% CI]a 95 [88-98] Data cutoff: August 7, 2019. a2-sided Clopper-Pearson 95% confidence intervals. bPatient missed first 2 response assessments due to injury and inability to undergo imaging. After data cutoff, best response assessment was reported as PR. CR, complete response; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; PR-L, PR with lymphocytosis; SD, stable disease. 28

ASH 2019 - Global Phase 1/2 – CLL/SLL Cohort First in Human Study 29

AU-003 Study Schema Indication-Specific Expansion Cohorts RP2D DOSE ESCALATION RP2Da 320 mg DOSE EXPANSION All Dosed BID 320 mg qd RP2D All Dosed Dose (CLL/SLL) Pop Disease or Dose (CLL/SLL) 40 mg qd 3 (0) 160 mg bid R/R qd All B-cell 18 (2) 80 mg qd 4 (0) R/R bid All B-cell 21 (4) 160 mg qd 5 (2) R/R bid Non-GCB DLBCL 37 R/R bid CLL/SLL 71 (71) 320 mg qd 1 (0) R/R bid WM 20 160 mg bid 4 (2) R/R qd CLL/SLL 20 (20) Eligibility: Any Any WM 50 • WHO-defined B-cell malignancy R/R Any MCL 20 • >1 Prior therapy (relapsed cohorts only) TN Any CLL/SLL 21 (21) • No available higher priority treatment TN Any MCL 20 R/R Any HCL 11 • ECOG PS 0-2 R/R bid iNHL 40 • ANC >1000/µL, platelets >100000/µLb R/R bid Richter Transformation 15 • Adequate renal and hepatic function; no significant cardiac diseasec R/R bid All B-cell (prior BTKi) 3 (1) aBoth doses RP2D but as of protocol v.6, all patients were encouraged to switch to 160 mg bid. bGrowth factor/transfusion allowed. cAnticoagulation allowed. ANC, absolute neutrophil count; bid, twice daily; BTKi, Bruton tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB-DLBCL, germinal center B- cell–like diffuse large B-cell lymphoma; HCL, hairy cell leukemia; iNHL, indolent non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; qd, every day; R/R, relapsed/refractory; RP2D, recommended phase 2 dose; TN, treatment naïve; WM, Waldenström's macroglobulinemia. 30

Disease Response by Investigator Assessment R/R Overall TN (n=22) (n=101) (N=123) Overall Safety 31.7 (11.1- 24.3 (3.7- Follow-up, median (range), mo 29.5 (3.7-52.0) 47.6) 52.0) • 61.8% of patients (76/123) experienced at least one grade ≥3 AE and five Best response, n (%) patients discontinued treatment due to AEs; ORR 22 (100.0) 96 (95.0) 118 (95.9) • The most common AEs (≥ 20%) were CR 5 (22.7) 14 (13.9) 19 (15.4) contusion (47.2%), upper respiratory CRi tract infection (42.3%), diarrhea (31.7%), 0 1 (1.0) 1 (0.8) cough (29.3%), headache (23.6%), and PR 17 (77.3) 73 (72.3) 90 (73.2)a fatigue (20.3%); PR-L 0 8 (7.9) 8 (6.5) • 47.2% of patients (58/123) experienced SD at least one serious AE; and 0 4 (4.0) 4 (3.3) • One patient experienced a fatal AE, Discontinued before first 0 1 (1.0) 1 (0.8) assessment, n (%) neoplasm-malignant recurrent squamous cell carcinoma, considered unrelated to treatment drug by the study investigator. Event rate remaining in response 95.2 (70.7- 97.6 (90.8- 97.2 (91.5- at 12 mo, % (95% CI)b 99.3) 99.4) 99.1) Data cutoff: May 8, 2019. CR, complete response; CRi, complete response with incomplete bone marrow recovery; ORR, overall response rate; PR, partial response; PR-L, partial response with lymphocytosis; R/R, relapsed/refractory; SD, stable disease; TN, treatment-naïve. aAs of data cutoff (May 8, 2019), 4 patients met criteria for CR except required bone marrow to confirm; of these, 2 submitted bone marrow after data cutoff and confirmed CR. B Duration of response is summarized only for responders. Estimated using Kaplan-Meier method. 31

Disease Response by Investigator Assessment Patients With Del(17p) Overall TN (n=3) R/R (n=13) (n=16) Overall Safety Follow-up, median 34.8 (31.8- 24.5 (9.4- 31.2 (9.4- • 61.8% of patients (76/123) experienced at (range), mo 35.3) 43.5) 43.5) least one grade ≥3 AE and five patients discontinued treatment due to AEs; Best response, n (%) • The most common AEs (≥ 20%) were ORR 3 (100.0) 12 (92.3) 15 (93.8) contusion (47.2%), upper respiratory tract infection (42.3%), diarrhea (31.7%), cough CR 0 1 (7.7) 1 (6.3) (29.3%), headache (23.6%), and fatigue PR 3 (100.0) 9 (69.2) 12 (75.0) (20.3%); • 47.2% of patients (58/123) experienced at PR-L 0 2 (15.4) 2 (12.5) least one serious AE; and SD 0 1 (7.7) 1 (6.3) • One patient experienced a fatal AE, neoplasm-malignant recurrent squamous Event rate remaining cell carcinoma, considered unrelated to in response at 12 mo, 100 (NE-NE) 100 (NE-NE) 100 (NE-NE) treatment drug by the study investigator. % (95% CI)a Data cutoff: May 8, 2019. CR, complete response; CRi, complete response with incomplete bone marrow recovery; NE, not evaluable; ORR, overall response rate; PR, partial response; PR-L, partial response with lymphocytosis; R/R, relapsed/refractory; SD, stable disease; TN, treatment-naïve. a Duration of response is summarized only for responders. Estimated using Kaplan-Meier method. 32

Waldenström’s Macroglobulinemia 33

Zanubrutinib Efficacy in WM Favorable response depth and durability Overall Response Rate (ORR) Progression Free Survival (PFS) Best Response in zanubrutinib WM Overall TN RR Evaluable for 73 24 49 efficacy, n 95% CI Median Follow-up 23.9 mo 12.3 mo 24.8 mo Mod. 6th IWWM Response Criteria (IgM decreases only, and not extramedullary disease) Median Prior Lines 0 2 (1-8) of Therapy ORR 92% 96% 90% MRR 82% 87% 78% No. of patients at risk CR/VGPR1 42% 29% 49% PR 40% 58% 31% 1 One R/R patient achieved a CR, TN: treatment naïve; RR: relapsed refractory; Data cutoff 16 September 2018. Source: Trotman et al. EHA 2019 34

Ibrutinib Efficacy in WM Overall Response Rate (ORR) Progression Free Survival (PFS) Best Response ibrutinib Enrolled, n 63 100 Median Time-on-Treatment 19.1 months free 90 80 Modified 3rd IWWM 70 Response Criteria (IgM only) 60 50 Median Prior Lines of Tx 2 (1-9) 40 Survival (%) 30 20 ORR, n (%) 57 (90%) 10 Probability - Progression of Probability 0 MRR 46 (73%) VGPR 10 (16%) 0 3 6 9 12 15 18 21 24 27 30 No. of Subjects at Risk Month Median IgM Reduction (g/L) 35.2 to 8.8 (75%) 63 62 59 55 50 50 45 37 24 17 8 Median Hb Change (g/dl) 10.5 to 13.8 Source: Treon et al., NEJM, 2015 35

Mantle Cell Lymphoma 36

Zanubrutinib Efficacy in R/R MCL From U.S. approved label Best Response Zanubrutinib RR RR Study BGB-3111-206 BGB-3111-AU-003 Source Ph2 study Ph1/2 study Evaluable for efficacy, n 86 32 Median DoR in months 19.5 (16.6, NE) 18.5 (12.6, NE) Response Criteria Lugano 2014 Median Prior Lines of Therapy 2 (1-4) 1 (1-4) ORR 84% 84% CR 59% 22%* PR 24% 62% The most common adverse reactions (> 10%) with BRUKINSA were decreased neutrophil count, decreased platelet count, upper respiratory tract infection, decreased white blood cell count, decreased hemoglobin, rash, bruising, diarrhea, cough, musculoskeletal pain, pneumonia, urinary tract infection, blood in the urine (hematuria), fatigue, constipation, and hemorrhage. The most frequent serious adverse reactions were pneumonia (11%) and hemorrhage (5%). Of the 118 patients with MCL treated with BRUKINSA, eight (7%) patients discontinued treatment due to adverse reactions in the trials. The most frequent adverse reaction leading to treatment discontinuation was pneumonia (3.4%). One (0.8%) patient experienced an adverse reaction leading to dose reduction (hepatitis B). * FDG-PET scans were not required for response assessment. RR: relapsed refractory; NE: not estimable; DoR: duration of response. Source: BrukinsaTM U.S. label 37

CLL/SLL 38

Zanubrutinib Efficacy in CLL/SLL Frequent and durable responses – Phase 1/2 Overall Response Rate (ORR) Progression Free Survival (PFS) zanubrutinib TN CLL R/R CLL Total CLL n 16 50 66 Median follow- - free 7.6 14.0 10.5 up (mo) Best Response ORR 16 (100%) 46 (92%) 62 (94%) CR 1 (6%) 1 (2%) 2 (3%) Survival (%) PR 13 (81%) 41 (82%) 54 (82%) PR-L 2 (13%) 4 (8%) 6 (9%) Probability Progression of Probability SD 0 3 (6%) 3 (5%) Non-evaluable* 0 1 (2%) 1 (2%) No. of Subjects at Risk Month 66 66 62 53 45 37 27 25 19 11 9 6 4 *Discontinuation prior to first assessment Source: Seymour et al. 14-ICML 2017 (abstract 237) poster 39

Zanubrutinib Efficacy in CLL/SLL Frequent and durable responses – Phase 2 Best Overall Response by IRC (ORR) Progression Free Survival by IRC (PFS) zanubrutinib Total CLL n 91 Median follow-up (mo) 15.1 Best Response ORR 77 (84.6%) CR 3 (3.3%) PR 54 (59.3%) PR-L 20 (22.0%) SD 4 (4.4%) Non-evaluablea 3 (3.3%) aMissing anatomy imaging for 2 patients, and without evidence of response maintenance for at least 2 months for 1 patient, separately. Source: Xu et al. 15-ICML 2019. 40

Ibrutinib Efficacy in CLL/SLL Overall Response Rate (Relapsed / Refractory) Progression Free Survival (Relapsed / Refractory) n 85 free Median FU (mo) 20.9 Best Response ORR 75 (88%) CR 2 (2%) PR 58 (68%) Survival PR-L 15 (18%) SD NR PD NR Probability - Progression of Probability Overall Response Rate (Treatment-Naïve) Progression Free Survival (Treatment-Naïve) n 136 free Median FU (mo) 18.4 - Best Response ORR 117 (86%) CR 5 (4%) PR 107 (79%) PR-L 5 (4%) Survival (%) SD NR PD NR Probability Progression of Probability Source: For TN, Burger, et al New Engl J Med 2015. For R/R, Byrd, et al New Engl J Med 2013 41

Follicular Lymphoma 42

Zanubrutinib Plus Obinutuzumab Combination in Follicular Lymphoma Data from separate trials Zanubrutinib + FL Zanubrutinib Ibrutinib Obinutuzumab Idelalisib Obinutuzumab Source ICML 20191 ASH 20172 ASH 20163 JCO 20134 NEJM 20145 n 36 17 110 34 72 prior alkylator and CD20, prior alkylator and CD20, median 2 prior lines of mixed rituximab-sensitive alkylator and rituximab- Population mixed rituximab-sensitive last response <12 therapy, range 1-8 and -refractory refractory relapse and -refractory months Follow-up (med) 20.1 mo 7.8 mo 27.7 mo 33.7 mo NR ORR 72% 41% 21% 50% 54% CR 39% 18% 11% 18%6 6% • Overall response rate and complete responses to date compare favorably to those achieved with respective single-agents and recently approved therapies Notes: data on slide are cross-trial comparison; Source: 1. Tam et al., ICML 2019; 2. Tam et al., ASH (abstract 152), 2017; 3. Gopal, et al ASH 2016; 4. Salles, et al J Clin Oncol 2013; 5. Gopal, et al N Engl J Med 2014; 6. 18% represents complete response rate in the 40 indolent lymphoma patient population that include 34 FL patients. 43

Various B-cell Malignancies 44

Zanubrutinib Responses Across Additional B-Cell Malignancies MZL MCL MCL FL FL DLBCL China CSCO Source ASH 20171 ICML 20193 pivotal data ASH 20171 ASH 20171 20184 ASH20182 n 9 48 85 17 26 26 Follow-up 7.0 mo 16.7 mo 35.9 wk 7.8 mo 9.5 mo 4.2 mo (med) Prior Lines 2 (1-8) 1 (1-4) 2 (1-4) 2 (1-8) 3 (1-9) 2 (1-10) (med) ORR 78% 85% 84% 41% 42% 31% CR 0 29%* 59%** 18% 8% 15% VGPR -- -- -- -- -- -- PR/PR-L 78% 56% 25% 24% 35% 15% MR -- -- -- -- -- -- • Despite relatively early follow-up, responses were observed in multiple B-cell malignancies • Consistency across tumor types suggests that zanubrutinib is a highly active BTK inhibitor * CT response assessment; ** PET-CT response assessment. Source: 1. Tam et. al., ASH 2017; 2. Song et al., ICML 2019; 3. Tam et al., ICML 2019; 4. Song et. al., CSCO 2018 45

Pooled Safety 46

Pooled Safety Data* Zanubrutinib Zanubrutinib Acalabrutinib6 Ibrutinib Background EHA 20181 EHA 20192 Rate n 476 682 612 7565; 1,124b; 2,0904-2,1523 1,605c Major hemorrhage % 2% 2.5% 2.8% 4%5 (Gr≥3) (2%) (2.1%) (2.0%) (3%)5 [events/100 pt. yrs.] [2.07] - [3.0]3 [1.9]3 Atrial fibrillation % ~2% 1.9% 2.9% 9%c (Gr≥3) (0.2%) (0.6%) (1.0%) (4.1%)c [events/100 pt. yrs.] [1.56] - [3.3]4 [0.84]4 Diarrhea ~15% 19.4% 40% 39%c (Gr≥3) (1%) (0.9%) (2.1%) (3%)c Median exposure, mo 7.0 (0.02-36.05) 13.4 (6.1-19.6) 18.5 (0.03- 14.8moc a (25th-75th percentile) 37.4)# (range)# * Pooled safety data from separate trials and sources. Limitations regarding cross-trial comparisons apply. Sources: 1 Tam et al, EHA 2018; 2 Tam et al, EHA 2019; 3 Caron, F Blood Advances 1:12 2019; 4 Leong, D Blood 128:1 2016; 5 O’Brien S Clin Lymphoma Myeloma & Leukemia 18:10 2018; 6 Byrd et al, ASH 2017; a Median treatment duration; b Data from label out of 1,124 patients; c Data from label out of 1,605 patients 47

EX-99.2

Exhibit 99.2

BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019

• Oral presentation on data from Phase 1b trial in patients with platinum-resistant ovarian cancer

CAMBRIDGE, Mass. and BEIJING, China, December 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary data from an ongoing Phase 1b trial of investigational anti-PD-1 antibody tislelizumab in combination with investigational tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer, which demonstrated antitumor activity and was generally well tolerated. Results from the Phase 1b clinical trial were presented at the 2019 European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress on December 13, 2019 in Geneva, Switzerland.

“Tislelizumab and sitravatinib have both demonstrated antitumor activity as single agents, so we’re encouraged by the early evidence showing the potential for these two agents to work together to treat advanced solid tumors, including platinum-resistant ovarian cancer,” said Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “We continue to make progress in the collaboration with Mirati Therapeutics and we look forward to continued enrollment in the trial and further clinical data on the combination of tislelizumab and sitravatinib, a compound that has a unique tyrosine kinase inhibition profile.”

“We were eager to enter into this collaboration with BeiGene because we believe sitravatinib, a spectrum-selective receptor tyrosine kinase inhibitor, may help increase the activity of anti-PD-1 antibodies such as tislelizumab in patients whose solid tumors exhibit resistance,” said Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer, Mirati Therapeutics, Inc. “The initial results from this Phase 1b trial suggest further development of this combination for the treatment of advanced solid tumors, including platinum-resistant ovarian cancer, is warranted.”

___________________________________________________________________________________

Summary of Preliminary Results from the Phase 1b Trial in Platinum-Resistant Ovarian Cancer

Abstract 94O

This open-label, multi-center Phase 1b trial (NCT03666143) of tislelizumab in combination with sitravatinib consists of nine disease-specific cohorts in patients with advanced solid tumors. The results presented at ESMO I-O were from cohort E in 20 patients with recurrent platinum-resistant ovarian cancer who did not have prior exposure to anti-PD-1/PD-L1 agents. Patients were treated with tislelizumab at 200 mg IV every three weeks and sitravatinib at 120mg orally once daily. At the data cutoff of July 17, 2019, 17 patients were evaluable and preliminary results included:

• Seven patients achieved a partial response (PR), including four confirmed PRs; the overall response rate (ORR) was 23.5% (4/17, 95% CI: 6.8%, 49.9%); eight patients achieved stable disease (SD);

• The median duration of response (DoR) was not reached (95% CI: 12.29 weeks, not reached);

• The median progression-free response (PFS) was 18 weeks (95% CI: 12.29 weeks, not reached), and the PFS rate at 3 months and 6 months was 88.2% (95% CI: 60.6%, 96.9%) and 35.3% (95% CI: 9.0%, 63.8%), respectively;

• All 20 patients in this cohort experienced treatment-emergent adverse events (TEAEs) of any grade;

• Fifteen patients (75%) experienced at least one grade ≥ 3 TEAE, with the most common being hypertension (25%) and fatigue (10%);

• Immune-related TEAEs were hypothyroidism (20%), diarrhea (15%), and rash (15%);

• Six patients (30%) discontinued the study treatment due to TEAEs; and

• Two patients experienced TEAEs leading to death, abdominal pain and respiratory failure, both of which were considered unrelated to treatment by the study investigator.

BeiGene and Mirati entered into an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand in January 2018. Clinical trials for tislelizumab and

___________________________________________________________________________________

sitravatinib are ongoing in patients with non-small cell lung cancer, renal cell carcinoma, melanoma, hepatocellular cancer and gastric cancer.

About Tislelizumab

Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologics program and is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Select ongoing clinical trials of tislelizumab include a Phase 3 clinical trial in patients with second-line or third-line non-small cell lung cancer (NSCLC); a Phase 3 clinical trial in first-line patients with hepatocellular carcinoma (HCC); a Phase 3 clinical trial in second-line patients with esophageal squamous carcinoma (ESCC); a Phase 3 clinical trial in first-line patients with gastric cancer (GC); a Phase 3 clinical trial in first-line patients with ESCC; and a Phase 2 clinical trial in second- or third-line patients with HCC. The aforementioned trials are enrolling patients in multiple countries, including the United States, Europe, and China.

In addition to a pivotal Phase 2 clinical trial in patients with relapsed or refractory (R/R) classical Hodgkin’s lymphoma (cHL) and a pivotal Phase 2 clinical trial in patients with locally advanced or metastatic urothelial cancer, BeiGene is conducting a Phase 3 clinical trial in first-line patients with non-squamous NSCLC; a Phase 3 clinical trial in first-line patients with squamous NSCLC; a Phase 3 clinical trial in patients with first-line nasopharyngeal cancer (NPC); a Phase 3 clinical trial in first-line patients with urothelial carcinoma (UC); a Phase 3 clinical trial in patients with localized ESCC; and a Phase 2 trial in patients with MSI-H or dMMR solid tumors. These studies have been enrolling patients primarily in China.

New drug applications (NDA) for tislelizumab in patients with R/R cHL and in patients with previously treated locally advanced or metastatic UC have been accepted and granted priority review by the China National Medical Products Administration (NMPA, formerly known as CFDA). BeiGene has full development and commercial rights to tislelizumab worldwide.

___________________________________________________________________________________

About Sitravatinib

Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being evaluated in combinations of anti-PD-1 checkpoint inhibitors, in patients whose cancers have progressed despite treatment with a checkpoint inhibitor. Sitravatinib's potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are refractory to prior immune checkpoint inhibitor therapy, including the ongoing potentially registration-enabling Phase 3 trial of sitravatinib in combination with a checkpoint inhibitor in non-small cell lung cancer (NSCLC). In addition, sitravatinib combinations with checkpoint inhibitors are being evaluated in selected checkpoint inhibitor naïve patients.

Sitravatinib is also being evaluated as a single-agent in a Phase 1b expansion clinical trial emphasizing enrollment of patients whose tumors harbor specific mutations in the CBL protein. When CBL is inactivated by mutation, multiple RTKs, including TAM, VEGFR2 and KIT, are dysregulated and may act as oncogenic tumor drivers in NSCLC and melanoma.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,000 employees in the United States, China, Australia, and Europe; BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets and distributes BRUKINSA™ (zanubrutinib) and in China, the Company markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) under a license from Celgene Logistics Sarl, a Bristol-Myers Squibb company.¹ 

¹ABRAXANE® is registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company.

___________________________________________________________________________________

About Mirati Therapeutics

Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnology company dedicated to advancing novel therapeutics that extend the lives of patients by directly addressing the genetic and immunological drivers of cancer. Mirati's lead drug candidate, sitravatinib, is designed to selectively target a spectrum of tyrosine kinases implicated in both tumor growth and the suppression of immune responses to tumors. Sitravatinib has demonstrated durable responses in lung cancer patients whose cancer has progressed despite treatment with checkpoint inhibitors - an area of significant unmet medical need. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are refractory to prior immune checkpoint inhibitor therapy, including a potentially registration-enabling Phase 3 trial of sitravatinib in combination with a checkpoint inhibitor in non-small cell lung cancer (NSCLC) that is currently enrolling patients.

Mirati is also developing novel inhibitors of KRAS mutations including MRTX849, a potent and selective inhibitor of KRAS G12C. This previously difficult to drug target is present in approximately 14% of NSCLC adenocarcinomas, 4% of colorectal cancer as well as smaller percentages of several other difficult-to-treat cancers. MRTX849 is being evaluated in a Phase 1/2 clinical trial as a treatment for patients with KRAS G12C-positive tumors. Our research on G12C has led to breakthroughs in targeting other KRAS mutations including G12D which drives tumor growth in more patients than G12C and includes pancreatic, colorectal and other types of cancer. For more information, visit www.mirati.com.

BeiGene’s Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from ongoing clinical trials of tislelizumab and sitravatinib, the mechanism of action of tislelizumab, BeiGene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab and sitravatinib. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if

___________________________________________________________________________________

approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Mirati’s Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the business of Mirati Therapeutics, Inc. (“Mirati”) that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Mirati’s development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, including without limitation the sitravatinib clinical trials referenced above, and the potential benefits of and markets for Mirati’s product candidates. Forward-looking statements are typically, but not always, identified by the use of words such as "may," “will,” "would," "believe," "intend," "plan," "anticipate," "estimate," “expect,” and other similar terminology indicating future results. Forward-looking statements are based on current expectations of management and on what management believes to be reasonable assumptions based on information currently available to them, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation potential delays in development timelines, negative clinical trial results, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati’s recent filings on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission. Except as required by law, Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact

Craig West

+1 857-302-5189

ir@beigene.com

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or +1 857-302-7596

media@beigene.com

___________________________________________________________________________________

EX-99.3

Exhibit 99.3

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

• Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)

• Zanubrutinib Demonstrated Advantages in Safety and Tolerability Compared to Ibrutinib

• ASPEN is the Largest Phase 3 Trial in Waldenström’s Macroglobulinemia and the First Comparative Trial Readout for BTK Inhibitors

• Company to Hold Investor Conference Call and Webcast Today at 8:30 AM ET

CAMBRIDGE, Mass. and BEIJING, China, December 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced results from the Phase 3 ASPEN trial comparing its BTK inhibitor BRUKINSA™ (zanubrutinib) to ibrutinib for the treatment of Waldenström’s macroglobulinemia (WM). While the trial did not achieve statistical significance on its primary endpoint of superiority in complete response (CR) and very good partial response (VGPR) rates for zanubrutinib compared to ibrutinib, zanubrutinib demonstrated a higher VGPR rate as well as improvements in safety and tolerability in this first randomized comparative trial to read out within the BTK inhibitor class.

The ASPEN trial is a randomized Phase 3 trial in 229 patients with WM conducted in 61 centers in Europe, Australia, and the United States. The study includes two cohorts, a randomized cohort (cohort 1) consisting of 201 patients with a MYD88 mutation and a non-randomized cohort (cohort 2) in which 28 patients with MYD88 wild-type (MYD88^WT) received zanubrutinib because they have historically responded poorly to ibrutinib therapy.

The randomized cohort 1 enrolled 102 patients (including 83 relapsed or refractory (R/R) patients and 19 treatment-naïve (TN) patients) in the zanubrutinib arm and 99 patients (including 81 R/R patients and 18 TN patients) in the ibrutinib arm. Patients in the zanubrutinib arm were assigned to receive zanubrutinib 160 mg twice daily (BID) and patients in the ibrutinib arm received 420 mg of ibrutinib once daily (QD).

Results from cohort 1 in the Phase 3 ASPEN trial, as of the data cutoff date of August 31, 2019 with a median follow-up of 19.4 months, include:

1

• In R/R patients, the VGPR rate as assessed by independent review committee (IRC) was 28.9% in the zanubrutinib arm and 19.8% in the ibrutinib arm (no patients achieved a CR in either arm). The difference was not statistically significant (2-sided p=0.1160);

• In the overall patient population, the VGPR rate as assessed by IRC was 28.4% in the zanubrutinib arm and 19.2% in the ibrutinib arm (no patients achieved a CR in either arm). The difference was not statistically significant (2-sided descriptive p=0.0921);

• In the R/R patient population, the major response rate (MRR), which is the rate of partial response (PR) or better, as assessed by IRC was 78.3% in the zanubrutinib arm and 80.2% in the ibrutinib arm; in the overall patient population, the MRR was 77.5% in the zanubrutinib arm and 77.8% in the ibrutinib arm;

• While the trial was not powered to detect a statistically significant improvement in progression free survival (PFS), and follow-up data for PFS is still short, early PFS and overall survival (OS) data for zanubrutinib were directionally consistent with the higher VGPR rates in the zanubrutinib arm:

o The 12-month PFS rate was 92.4% (83.8-96.5) in R/R patients and 89.7% (81.7-94.3) in all patients in the zanubrutinib arm, compared to 85.9% (75.9-91.9) in R/R patients and 87.2% (78.6-92.5) in all patients in the ibrutinib arm; and

o The 12-month OS rate was 98.8% (91.6-99.8) for R/R patients and 97.0% (90.9-99.0) for all patients in the zanubrutinib arm, compared to 92.5% (84.1-96.6) in R/R patients and 93.9% (86.8-97.2) in all patients in the ibrutinib arm;

• Grade >3 adverse events (AEs) were 58.4% in the zanubrutinib arm and 63.3% in the ibrutinib arm. In the zanubrutinib arm, four (4.0%) patients discontinued treatment due to AEs and there was one (1.0%) fatal adverse event; in the ibrutinib arm, nine patients (9.2%) discontinued due to AEs and there were four (4.1%) fatal adverse events;

• For AEs of special interest for BTK inhibitors, atrial fibrillation/flutter of any grade was 2.0% in the zanubrutinib arm and 15.3% in the ibrutinib arm; minor bleeding was 48.5% for zanubrutinib and 59.2% for ibrutinib; major hemorrhage was 5.9% for zanubrutinib and 9.2% for ibrutinib; and diarrhea was 20.8% for zanubrutinib and 31.6% for ibrutinib; and

2

• The rate of neutropenia was higher in the zanubrutinib arm (29.7%) as compared to the ibrutinib arm (13.3%).

Summary Tables:

	R/R		Overall
Efficacy	Zanubrutinib (N = 83)	Ibrutinib (N = 81)	Zanubrutinib (N = 102)	Ibrutinib (N = 99)
VGPR + CR Rate	28.9%	19.8%	28.4%	19.2%
PFS (12 month) (CI)	92.4% (88.9 - 98.8)	85.9% (75.9 - 91.9)	89.7% (81.7 - 94.3)	87.2% (78.6 - 92.5)
OS (12 month) (CI)	98.8% (91.6 - 99.8)	92.5% (84.1 - 96.6)	97.0% (90.9 - 99.0)	93.9% (86.8 - 97.2)

	Zanubrutinib	Ibrutinib
Safety	Overall (n = 101)	Overall (n = 98)
Grade >3 AEs	58.4%	63.3%
Treatment discontinuation due to AEs	4 (4.0%)	9 (9.2%)
Fatal AEs	1 (1.0%)	4 (4.1%)
Atrial fibrillation / flutter of any grade	2.0%	15.3%
Minor bleeding	48.5%	59.2%
Major hemorrhage	5.9%	9.2%
Diarrhea	20.8%	31.6%
Neutropenia	29.7%	13.3%

“Our researchers sought to design a BTK inhibitor that would improve efficacy and decrease side effects in patients by maximizing BTK inhibition and minimizing off-target binding. We took a bold approach to our clinical development plan by evaluating zanubrutinib directly against ibrutinib in patients with WM and are encouraged by the improvements in VGPR rates and safety,” said Jane Huang, M.D., Chief Medical Officer, Hematology at BeiGene. “The ASPEN trial, which was the largest prospective trial for patients with WM ever run, showed consistent safety advantages for patients treated with zanubrutinib compared to ibrutinib. While falling short of a statistically significant improvement in CR and VGPR, we believe the trial demonstrated that zanubrutinib is a highly potent BTK inhibitor that has clinical benefit and trends toward increased response quality.”

Dr. Huang continued, “Today’s results are consistent with what we know about zanubrutinib from our broad clinical development program – that it is a more selective BTK inhibitor with beneficial pharmacokinetics designed to provide deep, meaningful

3

responses for many patients. We plan to discuss our findings with regulatory authorities in the U.S. and Europe and plan to submit these data for presentation, with additional analysis, to an upcoming medical meeting. In addition, we will continue to evaluate zanubrutinib compared to ibrutinib in our ongoing Phase 3 ALPINE trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).”

“WM is a devastating and incurable disease with significant morbidity. These meaningful results help us advance the understanding of the role of BTK specificity and off-target effects during treatment,”said Constantine S. Tam, M.D., Disease Group Lead for Low Grade Lymphoma and Chronic Lymphocytic Leukemia at the Peter MacCallum Cancer Center and Director of Hematology at St. Vincent’s Hospital, Australia, and a member of the steering committee and principal investigator for the ASPEN trial. “Despite not reaching the primary endpoint, 28.4% of zanubrutinib patients achieved VGPR as compared to 19.2% in the ibrutinib arm, and zanubrutinib had a more favorable safety profile, suggesting improved clinical benefit for zanubrutinib over standard BTKi therapy in the treatment of patients with WM.”

About the ASPEN trial

The Phase 3 randomized, open-label, multicenter ASPEN clinical trial (NCT03053440) evaluated BRUKINSA versus ibrutinib in people with relapsed/refractory (R/R) or treatment-naïve (TN) Waldenström’s macroglobulinemia. The primary objective was to establish superiority of BRUKINSA compared to ibrutinib as demonstrated by the proportion of people achieving complete response (CR) or very good partial response (VGPR). Secondary endpoints included major response rate, duration of response and progression-free survival, and safety, measured by incidence, timing and severity of treatment-emergent adverse events. The pre-specified analysis populations for the trial included the overall population (n=201) and R/R patients (n=164).

Results of cohort 2 were previously presented at the 24th Congress of European Hematology Association (EHA) and showed an overall response rate (ORR) of 80.8%, a major response rate (MRR; partial response or better) of 53.8% and a VGPR rate of 23.1%.

The data from the study were masked and the results were first available for analysis this past week. The Company plans to submit the full ASPEN results for presentation to an upcoming medical congress.

4

BeiGene Conference Call and Webcast Information
Investors and analysts are invited to join the conference call on Monday, December 16 at 8:30 a.m. ET using the following dial-in information:

U.S. Toll-Free: +1 (844) 461-9930Hong Kong: +852 5819-4851China: +86 400-682-8609Conference ID: 2885995

A live webcast of the conference call and the slides from the presentation can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.

About the Zanubrutinib Clinical Trial Program

Clinical trials of zanubrutinib include:

• Fully-enrolled Phase 3 ASPEN clinical trial in patients with Waldenström’s macroglobulinemia (WM) comparing zanubrutinib to ibrutinib (NCT03053440), currently the only approved BTK inhibitor for WM;

• Phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (NCT03336333);

• Phase 3 ALPINE trial comparing zanubrutinib to ibrutinib in patients with relapsed/refractory (R/R) CLL/SLL (NCT03734016);

• Phase 2 trial in combination with GAZYVA^® (obinutuzumab) in patients with R/R follicular lymphoma (FL) (NCT03332017);

• Phase 3 trial comparing zanubrutinib and rituximab to bendamustine and rituximab in patients with untreated MCL (NCT04002297);

• Phase 2 MAGNOLIA trial in patients with R/R marginal zone lymphoma (MZL) (NCT03846427);

• Phase 2 ROSEWOOD trial (NCT03332017) in China comparing obinutuzumab and zanubrutinib vs obinutuzumab alone in treating patients with R/R FL;

• Completed Phase 2 trials in patients with R/R MCL (NCT03206970) and R/R CLL/SLL (NCT03206918); and

5

• Completed enrollment in Phase 2 clinical trial in patients with WM (NCT03332173).

About BRUKINSA™ (zanubrutinib)

BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), discovered by BeiGene scientists, that is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies.

BRUKINSA was approved by the U.S. FDA to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy on November 14, 2019. This indication was approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

New Drug Applications (NDAs) in China for relapsed refractory (R/R) MCL and R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have been accepted by the China National Medical Products Administration (NMPA) and granted priority review and are pending approval.

BRUKINSA is not approved for use outside the United States. BRUKINSA is not approved for the treatment of Waldenström’s macroglobulinemia.

IMPORTANT SAFETY INFORMATION FOR BRUKINSA (ZANUBRUTINIB)

Warnings and Precautions

Hemorrhage

Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 2% of patients treated with BRUKINSA monotherapy. Bleeding events of any grade, including purpura and petechiae, occurred in 50% of patients treated with BRUKINSA monotherapy.

Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA

6

for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections

Fatal and serious infections (including bacterial, viral, or fungal) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher infections occurred in 23% of patients treated with BRUKINSA monotherapy. The most common Grade 3 or higher infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation have occurred.

Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

Cytopenias

Grade 3 or 4 cytopenias, including neutropenia (27%), thrombocytopenia (10%) and anemia (8%) based on laboratory measurements, were reported in patients treated with BRUKINSA monotherapy.

Monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.

Second Primary Malignancies

Second primary malignancies, including non-skin carcinoma, have occurred in 9% of patients treated with BRUKINSA monotherapy. The most frequent second primary malignancy was skin cancer (basal cell carcinoma and squamous cell carcinoma of skin), reported in 6% of patients. Advise patients to use sun protection.

Cardiac Arrhythmias

Atrial fibrillation and atrial flutter have occurred in 2% of patients treated with BRUKINSA monotherapy. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher events were reported in 0.6% of patients treated with BRUKINSA monotherapy. Monitor signs and symptoms for atrial fibrillation and atrial flutter and manage as appropriate.

Embryo-Fetal Toxicity

Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of

7

organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for at least 1 week after the last dose. Advise men to avoid fathering a child during treatment and for at least 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

Adverse Reactions

The most common adverse reactions in > 10% of patients who received BRUKINSA were neutrophil count decreased (53%), platelet count decreased (39%), upper respiratory tract infection (38%), white blood cell count decreased (30%), hemoglobin decreased (29%), rash (25%), bruising (23%), diarrhea (20%), cough (20%), musculoskeletal pain (19%), pneumonia (18%), urinary tract infection (13%), hematuria (12%), fatigue (11%), constipation (11%), and hemorrhage (10%). The most frequent serious adverse reactions were pneumonia (11%) and hemorrhage (5%).

Drug Interactions

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.

CYP3A Inducers: Avoid coadministration with moderate or strong CYP3A inducers.

Specific Populations

Hepatic Impairment:  The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.

INDICATION

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Please see full Prescribing Information at www.beigene.com/PDF/BRUKINSAUSPI.pdf and Patient Information at www.beigene.com/PDF/BRUKINSAUSPPI.pdf.

8

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,000 employees in the United States, China, Australia, and Europe; BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets and distributes BRUKINSA™ (zanubrutinib) and in China, the Company markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) under a license from Celgene Corporation Logistics Sarl, a Bristol-Myers Squibb company.¹ 

¹ABRAXANE® is registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company.

9

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data for patients from the ASPEN trial and advantages compared to ibrutinib; plans for regulatory discussions and submission of data from the ASPEN trial; BeiGene’s further advancement of, and anticipated clinical development, regulatory milestones and commercialization of its drug candidates; and continuing and further development and commercialization efforts and transactions with third parties. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor Contact

Craig West

+1 857-302-5189

ir@beigene.com

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or +1 857-302-7596

media@beigene.com

10

XML

Cover Document	Dec. 16, 2019
Cover page.
Document Type	8-K
Document Period End Date	Dec. 12, 2019
Entity Registrant Name	BEIGENE, LTD.
Entity Incorporation, State or Country Code	E9
Entity File Number	001-37686
Entity Tax Identification Number	98-1209416
Entity Address, Street Address	c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address 2	94 Solaris Avenue, Camana Bay
Entity Address, City or Town	Grand Cayman
Entity Address, Postal Zip Code	KY1-1108
Entity Address, Country	KY
City Area Code	345
Local Phone Number	949-4123
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of each class	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol	BGNE
Name of each exchange on which registered	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001651308
Amendment Flag	false